reverse transcriptase. However, the thiocarboxanilide derivatives selected for mutations at amino acid positions 100 (Leu -* Ile), 101 (Lys -> Ile/Glu), 103 (Lys --Thr/Asp) and 141 (Gly --Glu) in the HIV-1 reverse transcriptase. The compounds completely suppressed HIV-1 replication and prevented the emergence of resistant virus strains when used at 1. 3-6.6 ,IM-that is, 10 -to 25-fold lower than the concentration required for nevirapine and bis(heteroaryl)piperazine (BHAP) U90152 to do so. If UC42 was combined with the [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro-5"-(4"-amino-1",2"-oxathiole-2",2'-dioxide)]-f3-D-pentofuranosyl (TSAO) derivative of N3-methylthymine (TSAO-m3T), virus breakthrough could be prevented for a much longer time, and at much lower concentrations, than if the compounds were used individually. Virus breakthrough could be suppressed for even longer, and at lower drug concentrations, if BHAP was added to the combination of UC42 with TSAO-m3T, which points to the feasibility of two-or three-drug combinations in preventing virus breakthrough and resistance development.
The rapid emergence of HIV-1 strains resistant to several HIV-1-specific reverse transcriptase (RT) inhibitors in cell culture {i.e., nevirapine, pyridinone, tetrahydroimidazo [4,5,1-jk] [1, 4] benzodiazepin-2(1H)-one and -thione (TIBO), bis(heteroaryl)piperazine (BHAP), [2',5 '-bis-O-(tert-butyldimethylsilyl)-3'-spiro-5"-(4"-amino-1",2"-oxathiole-2",2"-dioxide)]-(3-D-pentofuranosyl (TSAO), quinoxaline} and in AIDS patients (i.e., nevirapine, pyridinone, BHAP) has caused majorconcem forfurther development of these inhibitors in the clinic (1-8, §, 1) However, HIV-1 resistance to one HIV-1-specific RT inhibitor does not necessarily imply cross-resistance to other HIV-1-specific RT inhibitors (5, 6, 9) . For example, HIV-1 strains containing the Leu-100 -> Ile mutation in their RT are resistant to TIBO R82913 and R82150 but not to nevirapine and TSAO derivatives. Also, HIV-1 strains containing the Glu-138 -> Lys mutation in their RT are resistant to TSAO derivatives but not to the other HIV-1-specific RT inhibitors, including BHAP and nevirapine (5, 6) . In contrast, the Tyr-181 -> Cys mutation in the RT of HIV-1 strains renders the mutant viruses resistant to virtually all HIV-1-specific RT inhibitors described so far (1, 2, 5, 6) . Therefore, we started to search
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for HIV-1-specific RT inhibitors that would suppress the replication of HIV-1 strains containing the most important resistance mutations in their RT (i.e., Tyr-181 -> Cys, Val-106 -> Ala, Glu-138 -> Lys, Leu-100 -> Ile, and Lys-103 -> Asn).
We identified five different compounds, distantly related to the oxathiin carboxanilide NSC 615985 (UC84) (10) and designated UC10, UC16, UC42, UC68, and UC81, that had a marked activity against these mutant HIV-1 strains. The parent compound, UC84, emerged several years ago from the National Institutes of Health (National Cancer Institute) screening program on AIDS as a potent and selective inhibitor of HIV-1 in cell culture (10) . As the RT mutations underlying resistance to the carboxanilide derivatives are different from those generated by other HIV-1-specific RT inhibitors-i.e., TSAO derivative of N3-methylthymine (TSAO-m3T) and BHAP U90152-we have rationally pursued combinations of these compounds in attempts to suppress the emergence of drug-resistant virus strains. Our data indicate that virus drugresistance development can be prevented in cell culture with the appropriate combinations of HIV-1-specific RT inhibitors at the appropriate concentrations.
MATERIALS AND METHODS
Test Compounds. Synthesis of TSAO-m3T has been described (11, 12 (13, 14) . The first set of primers (5'-GTAGAATTCT-GTTGACTCAGATTGG-3' and 5'-TTCTGCCAGTTCTA-GCTCTGCTTCT-3') gave a 900-bp product of the proviral RT gene. The second set of primers (5'-CCTGAAAATC-CATACAATACTCCAGTATTTG-3' and 5'-AGTGCTTT-GGTTCCTCTAAGGAGTTTAC-3') gave a 727-bp RT fragment covering amino acids 50-270.
RT Assay. The RT assay using recombinant HIV-1 RT was performed as described (15) . Their IC50 values ranged between 0.011 and 0.14 ,M (Table   1 ). In striking contrast with the prototype HIV-1-specific RT inhibitors nevirapine, BHAP, TIBO, pyridinone, and TSAOm3T, the thiocarboxanilide derivatives proved substantially more inhibitory to the cytopathicity of the RT/Cys-181 HIV-1 mutant in CEM cells. Higher IC50 values were noted for nevirapine, pyridinone, BHAP, TIBO, and TSAO-m3T (Table 2) .
Knockout Concentrations of the Thiocarboxanilide Derivatives. The thiocarboxanilide derivatives as well as BHAP U88104 and nevirapine were added to HIV-1(IIIB)-infected CEM cells at initial concentrations of 0.1 ,ug/ml (-0.3 AM), 0.5 ,ug/ml ('1.4 AM), and 2.5 ,ug/ml (-7 ,uM), which were kept constant throughout the experiment (10 subcultivations or 35 days). Virus emerged only in the presence of the lowest thiocarboxanilide compound concentrations (i.e., -0.3 ,uM) (on day 11 for UC10; day 8 for UC16; day 14 (Table 3) . Table 4 ). The three mutant HIV-1 strains containing the Lys-103 -> Asn mutation in their RT markedly differed in their sensitivity spectrum to the HIV-1-specific RT inhibitors (Table 4). The HIV-1/UC16(0.3) strains containing the Lys-101 -> Ile + Gly-141 -> Glu double mutation retained marked sensitivity to several compounds, including pyridinone, TSAOm3T, quinoxaline S2720, MKC-442, and even the thiocarboxanilide derivatives UC68 and UC81. Finally, the HIV-1/ UC42(0.3) mutant strain, containing the Thr mutation at position 103 of its RT, retained sensitivity to most HIV-1-specific RT inhibitors in the 0.39-1.5 ,uM range, except for (Table 5) .
However, when UC42 and TSAO-m3T were combined at their lowest concentrations (i.e., 0.11 ,uM for UC42 and 1.7 ,M for TSAO-m3T), the first signs of HIV-1-induced cytopathicity appeared at day 18 postinfection (50% CPE at day 25), whereas the combination of UC42 at 0.11 ,uM with TSAO-m3T at 4.2 ,M delayed virus breakthrough for 28 days postinfection (50% CPE at day 35)-i.e., for a much longer time than when both compounds were added to the cell cultures as single drugs at the same or at 2.5-fold (TSAO-m3T) or 6-fold (UC42) higher concentrations (Table 5) . Virus breakthrough was even more delayed with the combination of UC42 (0.28 ,uM) and TSAO-m3T (1.7 or 4.2 ,uM). Under these experimental conditions, virus was completely suppressed for up to 13 subcultivations (day 46 postinfection). Then, when the cultures were further subcultured in the absence of the test compounds for another 10 subcultivations (day 77 postinfection), no virus-induced cytopathicity became evident, and the cultures were proven to be viral antigen (p24) negative (data not shown). Again, when UC42 or TSAO-m3T was used at 2.5-to 5-fold higher concentrations as single drugs, virus could be suppressed only for 14 days (50% CPE at day 16) to 25 days (50% CPE at day 27) in cell culture. Thus, combination of UC42 with TSAO-m3T resulted in a marked delay or even complete prevention of mutant virus breakthrough, which was not obtained if the compounds were used individually at the same or even 2.5-to 5-fold higher concentrations. The triple combinations of UC42, TSAO-m3T, and BHAP afforded an even more striking effect (Table 5) . When added at lower concentrations, the triple-drug combinations were able to substantially delay (until day 39, 46, or 56) or even prevent emergence of resistant virus [no virus breakthrough by day 77 (22nd subcultivation)], whereas the highest single-drug concentrations could prevent virus breakthrough only until day 14 to day 21 (Table 5 ). All triple-drug combinations in which UC42 was combined at 0.28 ,uM were able to clear the HIV-1-infected CEM cell cultures from virus. Inhibitory Effect of Combinations of Different Test Compounds on HIV-1 RT Activity. The kinetics of wild-type HIV-1 RT was assessed in the presence of combinations of UC42 with other HIV-1-specific RT inhibitors-i.e., TSAO-m3T and BHAP U90252 at concentrations that were close to their IC50 
DISCUSSION
We have previously demonstrated that paired combinations of HIV-1 RT inhibitors that are presently the subject of clinical trials (i.e., nevirapine, TIBO, BHAP, pyridinone) did not prevent or delay the emergence of drug-resistant virus in cell culture (15) . In all cases, the RT mutation Tyr-181 --Cys appeared in the treated cell cultures. Therefore, we searched for HI V-1-specific RT inhibitors that could efficiently suppress the RT/Cys-181 mutant virus. The thiocarboxanilide derivatives clearly fulfill this premise. In addition, these compounds also markedly inhibit various other drug-resistant virus mutants-i.e., RT/Lys-138, RT/Ala-106 and RT/Ile-100 mutant strains.
We have previously demonstrated that TSAO-m3T loses antiviral activity against virus mutants containing Cys-181, Lys-138, and Ala-106 in their RT (5, 6, 14, 16) while retaining substantial inhibitory efficacy against the RT/Ile-100 and RT/Asn-103 virus mutants. Therefore, the antiviral sensitivity/resistance spectrum of TSAO and UC42 led us to the design of combination experiments with UC42, which apparently prevents mutations at RT positions 181, 138, and 106, together with TSAO-m3T, which prevents mutations at RT positions 103 and 100. Our observations indicate that the emergence of resistant virus could be dramatically delayed when both compounds were combined, as compared to singledrug treatment. This supports the concept that a rational combination of HIV-1-specific RT inhibitors that complement each other in terms of the virus drug-sensitivity/resistance profile may prove to be a useful strategy for delaying or preventing the emergence of resistant virus. The combination of UC42 and TSAO-m3T can be advocated based on the "mutually suppressive mutation" principle rather than a direct synergistic action at the RT level. Moreover, complete clearance of HIV-1 from the virus-infected cells could be obtained by double-or triple-drug combinations of HIV-1-specific RT inhibitors (i.e., UC42, TSAO-m3T, and BHAP) at concentrations that were significantly lower than the concentrations needed to achieve this virus "knockout" with the compounds used individually. Thus, the emergence of drug-resistant HIV-1 strains could be completely suppressed by using HIV-1-specific inhibitors and combinations thereof without the need of 2',3'-dideoxynucleoside derivatives (such as AZT).
Our study revealed two additional (not previously reported) mutations at amino acid positions 101 and 103 of the HIV-1 RT (i.e., Ile-101 and Thr-103). It would now seem imperative to generate a series of amino acid mutations at positions 101 and 103 of the HIV-1 RT by site-directed mutagenesis to obtain a better insight in the interaction of the HIV-1-specific RT inhibitors with their target site at HIV-1 RT.
We also found striking differences in the drug sensitivities of several RT/Asn-103 mutant viruses, although no mutations, other than Lys-103 -* Asn, were observed within the 50-to 270-amino acid domain of the HIV-1 RT. The fact that 2'-deoxy-3'-thiacytidine was equally inhibitory to the three RT/Asn-103 mutant strains (data not shown) argues against different growth-kinetic or -dynamic properties of these viruses that might otherwise explain the differential sensitivity to the HIV-1-specific RT inhibitors. One possible explanation is the presence of a mutation(s) in a region of HIV-1 RT that is located outside amino acids 50-270 and that has so far not been recognized as playing a significant role in the interaction of RT with the HIV-1-specific RT inhibitors. Also, it cannot be excluded that an additional mutation(s) occurred in a viral protein other than RT that is closely associated with the expression of RT activity. These different possibilities should be further explored.
The mutations that are predominantly selected in cell culture in the presence of the UC derivatives tend to be those located at position 101 or 103 of the RT. These mutations did not confer high-level resistance to the thiocarboxanilide derivatives. They could be easily suppressed by other HIV-1-specific RT inhibitors such as nevirapine, pyridinone, TSAO, or BHAP or even by higher concentrations of the thiocarboxanilides.
UC16, UC42, UC68, and UC81 are thiocarboxanilide esters, whereas UC10 represents a thiocarboxanilide oxime ether derivative. Although the ester derivatives proved highly effective in cell culture, they are expected to be unstable in vivo, resulting in rapid degradation to their free carboxylic acid. We found that the carboxylic acid derivative UC15 (containing an isopropoxy moiety instead of furanyl or thiophene) is completely inactive as an anti-HIV-1 agent (EC5o > 30 ,M) or anti-HIV-1 RT agent (IC50> 30 ,tM), whereas its corresponding isopropyl ester derivative (UC77) is inhibitory at an EC50 of 0.04 ,LM and an IC50 of 0.2 ,uM against HIV-1 and HIV-1 RT, respectively. These data clearly suggest that the UC ester derivatives are stable in cell culture, retaining their antiviral activity upon a 4-day exposure to the virus-infected cells. These observations were also in agreement with our findings that the UC10 and UC42 are not markedly converted to their corresponding free carboxylic acid derivative when incubated in the presence of 50% fetal calf serum in phosphate-buffered saline (pH 7.2) for 16 hr. However, oral studies in mice generally revealed relatively rapid plasma. clearance and poor oral bioavailability of the ester derivatives. In contrast, UC10 showed high oral bioavailability in mice (70%) and when it was administered to dogs the oral bioavailability ranged from 85% to 90% (17) , which points to the stability and high bioavailability of UC10 in vivo. Thus, UC10 can be considered as a stable thiocarboxanilide derivative, with a favorable pharmacokinetic profile that should be pursued as a candidate drug for clinical studies.
In conclusion, we have identified a series of HIV-1-specific thiocarboxanilide RT inhibitors that differ, in several aspects, from the HIV-1-specific RT inhibitors that are currently the subject of clinical trials (i.e., nevirapine, pyridinone, TIBO, and BHAP). They are 10-fold more inhibitory to wild-type HIV-1 and are also effective against the replication of mutant HIV-1 strains, which are resistant to most other HIV-1-specific RT inhibitors. Combination of the thiocarboxanilide derivatives with TSAO-m3T and/or BHAP in double-and/or triple-drug combinations markedly delayed or even fully prevented breakthrough of resistant virus under the experimental conditions where the individual drugs failed to do so and where other HIV-1-specific RT inhibitors (i.e., BHAP, nevirapine, TSAO-m3T, TIBO), whether used alone or in combination, also failed to do so.
